<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379506</url>
  </required_header>
  <id_info>
    <org_study_id>5172-079</org_study_id>
    <secondary_id>2015-003006-16</secondary_id>
    <secondary_id>MK-5172-079</secondary_id>
    <nct_id>NCT03379506</nct_id>
  </id_info>
  <brief_title>Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)</brief_title>
  <official_title>A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to Less Than 18 Years With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of&#xD;
      oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and&#xD;
      grazoprevir [GZR] 100 mg) and EBR/GZR (varying doses) pediatric granules in pediatric&#xD;
      hepatitis C virus (HCV)-infected participants who are 3 to &lt;18 years of age. Within each age&#xD;
      cohort (Cohort 1: 12 to &lt;18 years of age; Cohort 2: 7 to &lt;12 years of age; and Cohort 3: 3 to&#xD;
      &lt;7 years of age), a Mini Cohort of 7 participants will be enrolled first. For the oldest&#xD;
      cohort (Cohort 1), the Mini Cohort will assess ability to swallow a placebo tablet prior to&#xD;
      administering active FDC tablets; participants in Cohorts 2 and 3 will take pediatric&#xD;
      granules instead of a tablet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">July 23, 2020</completion_date>
  <primary_completion_date type="Actual">October 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of EBR at Steady State</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The AUC0-24hr of EBR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of EBR</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The Cmax of EBR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State Predose Drug Concentration (Ctrough) of EBR</measure>
    <time_frame>Week 4: Predose</time_frame>
    <description>The Ctrough of EBR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of EBR at Steady State</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The CL/F of EBR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24hr of GZR at Steady State</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The AUC0-24hr of GZR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GZR</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The Cmax of GZR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of GZR</measure>
    <time_frame>Week 4: Predose</time_frame>
    <description>The Ctrough of GZR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of GZR at Steady State</measure>
    <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
    <description>The CL/F of GZR at steady state (Week 4) was determined in each cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥1 Adverse Event (AE)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>The percentage of participants with ≥1 AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The percentage of participants discontinuing study therapy due to an AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants achieving SVR12, defined as hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after completing study therapy, was determined in each cohort.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>EBR/GZR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EBR/GZR FDC Tablet</intervention_name>
    <description>Participants who are 12 to &lt;18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.</description>
    <arm_group_label>EBR/GZR</arm_group_label>
    <other_name>MK-5172A</other_name>
    <other_name>ZEPATIER®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matched to EBR/GZR FDC tablet.</description>
    <arm_group_label>EBR/GZR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir Oral Granules</intervention_name>
    <description>Participants 3 to &lt;12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.</description>
    <arm_group_label>EBR/GZR</arm_group_label>
    <other_name>MK-5172</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir Oral Granules</intervention_name>
    <description>Participants 3 to &lt;12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.</description>
    <arm_group_label>EBR/GZR</arm_group_label>
    <other_name>MK-8742</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has documented chronic HCV genotype (GT) 1 or GT4 infection&#xD;
&#xD;
          -  Has the following liver disease staging assessment: absence of cirrhosis or&#xD;
             compensated cirrhosis&#xD;
&#xD;
          -  Has one of the following HCV treatment statuses:&#xD;
&#xD;
          -  GT1 and GT4: treatment-naïve (TN), defined as no prior exposure to any interferon&#xD;
             (IFN)-containing regimen, ribavirin (RBV), or other HCV-specific direct acting&#xD;
             antiviral (DAA) agent&#xD;
&#xD;
          -  GT1 only: treatment-experienced (TE) with no previous treatment with HCV specific DAA&#xD;
             agents.&#xD;
&#xD;
          -  If female is not pregnant, not breastfeeding, and is either not of childbearing&#xD;
             potential or follows the contraceptive guidance during the treatment period and for at&#xD;
             least 14 days after the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has evidence of decompensated liver disease manifested by the presence of or history&#xD;
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or other&#xD;
             signs or symptoms of advanced liver disease.&#xD;
&#xD;
          -  Is cirrhotic AND has a Child-Turcotte-Pugh score &gt;6, corresponding to a Child Class B&#xD;
             or C.&#xD;
&#xD;
          -  Is co-infected with Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Has evidence of past or present hepatitis B infection.&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent or is under&#xD;
             evaluation for other active or suspected malignancy.&#xD;
&#xD;
          -  Female expects to conceive or donate eggs from Day 1 through at least 14 days after&#xD;
             the last dose of study treatment or longer.&#xD;
&#xD;
          -  Has any of the following conditions: organ transplants other than cornea and hair;&#xD;
             poor venous access; history of gastric surgery or malabsorption disorders; any&#xD;
             clinically significant cardiac abnormalities/dysfunction that may interfere with&#xD;
             participant treatment, assessment, or compliance; any major medical condition which&#xD;
             might interfere with participant treatment, assessment, or compliance; history of a&#xD;
             medical/surgical condition that resulted in hospitalization within the 3 months prior&#xD;
             to enrollment; medical/surgical conditions that may result in a need for&#xD;
             hospitalization during the study duration; any medical condition requiring, or likely&#xD;
             to require, chronic systemic administration of corticosteroids, tumor necrosis factor&#xD;
             antagonists, or immunosuppressant drugs; life-threatening serious adverse event (SAE)&#xD;
             during the screening period; history of chronic hepatitis not caused by HCV.&#xD;
&#xD;
          -  If female has a positive urine pregnancy test within 24 hours before the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Is taking or plans to take prohibited medications, or is taking herbal supplements.&#xD;
&#xD;
          -  Has had previous HCV direct acting antiviral (DAA) treatment.&#xD;
&#xD;
          -  Is currently participating or has participated in a study with an investigational&#xD;
             compound within prior 30 days&#xD;
&#xD;
          -  Has significant emotional problems or a clinically significant psychiatric disorder&#xD;
             that may interfere with participant treatment, assessment, or compliance with the&#xD;
             protocol.&#xD;
&#xD;
          -  Has clinically relevant drug or alcohol abuse within prior 12 months that may&#xD;
             interfere with participant treatment, assessment, or compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0020)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital ( Site 0006)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Center for Advanced Pediatrics ( Site 0204)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston ( Site 0009)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0003)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh ( Site 0024)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation ( Site 0200)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center ( Site 0017)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Kinderklinik K10 ( Site 0105)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Starnberg ( Site 0107)</name>
      <address>
        <city>Starnberg</city>
        <zip>82319</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal GmbH ( Site 0104)</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WSOZ im.T.Browicza w Bydgoszczy ( Site 0800)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. dr W. Bieganskiego w Lodzi ( Site 0810)</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MED-POLONIA Sp. z o.o. ( Site 0808)</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge. ( Site 0062)</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <results_first_submitted>July 29, 2020</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grazoprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03379506/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and female participants 3 to &lt;18 years of age with chronic hepatitis C virus (HCV) genotype 1 (GT1) or GT4 were enrolled at 14 global study sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
          <description>Pediatric participants 12 to &lt;18 years of age received elbasvir (EBR) 50 mg / grazoprevir (GZR) 100 mg fixed dose combination (FDC) tablets once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
          <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
        </group>
        <group group_id="P4">
          <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
          <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
          <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
        </group>
        <group group_id="B4">
          <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.9"/>
                    <measurement group_id="B2" value="8.7" spread="1.2"/>
                    <measurement group_id="B3" value="3.7" spread="0.8"/>
                    <measurement group_id="B4" value="4.8" spread="1.3"/>
                    <measurement group_id="B5" value="9.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of EBR at Steady State</title>
        <description>The AUC0-24hr of EBR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their pharmacokinetic (PK) data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of EBR at Steady State</title>
          <description>The AUC0-24hr of EBR at steady state (Week 4) was determined in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their pharmacokinetic (PK) data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.97" upper_limit="2.94"/>
                    <measurement group_id="O2" value="2.79" lower_limit="2.31" upper_limit="3.37"/>
                    <measurement group_id="O3" value="1.71" lower_limit="1.36" upper_limit="2.15"/>
                    <measurement group_id="O4" value="3.15" lower_limit="2.52" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of EBR</title>
        <description>The Cmax of EBR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of EBR</title>
          <description>The Cmax of EBR at steady state (Week 4) was determined in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.15" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.17" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.11" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.22" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State Predose Drug Concentration (Ctrough) of EBR</title>
        <description>The Ctrough of EBR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
        <time_frame>Week 4: Predose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included. One participant in Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded had missing Ctrough data.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Predose Drug Concentration (Ctrough) of EBR</title>
          <description>The Ctrough of EBR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included. One participant in Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded had missing Ctrough data.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.76" lower_limit="47.20" upper_limit="75.67"/>
                    <measurement group_id="O2" value="59.43" lower_limit="48.67" upper_limit="72.58"/>
                    <measurement group_id="O3" value="34.61" lower_limit="28.00" upper_limit="42.77"/>
                    <measurement group_id="O4" value="68.92" lower_limit="54.32" upper_limit="87.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of EBR at Steady State</title>
        <description>The CL/F of EBR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of EBR at Steady State</title>
          <description>The CL/F of EBR at steady state (Week 4) was determined in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" lower_limit="19.25" upper_limit="28.75"/>
                    <measurement group_id="O2" value="12.21" lower_limit="10.10" upper_limit="14.75"/>
                    <measurement group_id="O3" value="9.94" lower_limit="7.89" upper_limit="12.53"/>
                    <measurement group_id="O4" value="8.98" lower_limit="7.16" upper_limit="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥1 Adverse Event (AE)</title>
        <description>The percentage of participants with ≥1 AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
        <time_frame>Up to 36 weeks</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥1 Adverse Event (AE)</title>
          <description>The percentage of participants with ≥1 AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
          <population>All randomized participants who received ≥1 dose of study drug are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="76.5"/>
                    <measurement group_id="O3" value="85.7"/>
                    <measurement group_id="O4" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to an AE</title>
        <description>The percentage of participants discontinuing study therapy due to an AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to an AE</title>
          <description>The percentage of participants discontinuing study therapy due to an AE is reported in each cohort. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
          <population>All randomized participants who received ≥1 dose of study drug are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)</title>
        <description>The percentage of participants achieving SVR12, defined as hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after completing study therapy, was determined in each cohort.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants who received ≥1 dose of study treatment are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)</title>
          <description>The percentage of participants achieving SVR12, defined as hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after completing study therapy, was determined in each cohort.</description>
          <population>All randomized participants who received ≥1 dose of study treatment are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="84.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24hr of GZR at Steady State</title>
        <description>The AUC0-24hr of GZR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hr of GZR at Steady State</title>
          <description>The AUC0-24hr of GZR at steady state (Week 4) was determined in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.08" upper_limit="1.94"/>
                    <measurement group_id="O2" value="1.42" lower_limit="1.00" upper_limit="2.02"/>
                    <measurement group_id="O3" value="0.77" lower_limit="0.48" upper_limit="1.23"/>
                    <measurement group_id="O4" value="1.66" lower_limit="1.16" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of GZR</title>
        <description>The Cmax of GZR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GZR</title>
          <description>The Cmax of GZR at steady state (Week 4) was determined in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.17" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.12" upper_limit="0.31"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.05" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.18" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ctrough of GZR</title>
        <description>The Ctrough of GZR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
        <time_frame>Week 4: Predose</time_frame>
        <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included. One participant in Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded had missing Ctrough data.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough of GZR</title>
          <description>The Ctrough of GZR at steady state (Week 4) was determined at steady state prior to dosing in each cohort.</description>
          <population>All randomized and treated participants who complied with the protocol sufficiently to ensure that their PK data was likely to exhibit the effects of treatment, according to the underlying scientific model, are included. One participant in Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded had missing Ctrough data.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.20" lower_limit="12.27" upper_limit="21.38"/>
                    <measurement group_id="O2" value="16.27" lower_limit="11.97" upper_limit="22.10"/>
                    <measurement group_id="O3" value="13.79" lower_limit="9.55" upper_limit="19.90"/>
                    <measurement group_id="O4" value="16.17" lower_limit="12.78" upper_limit="20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F of GZR at Steady State</title>
        <description>The CL/F of GZR at steady state (Week 4) was determined in each cohort.</description>
        <time_frame>Week 4: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 hours postdose</time_frame>
        <population>No participants are included in the analysis as the CL/F of GZR was not calculable due to nonlinear PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Age Cohort 1: 12 to &lt;18 Years: Mini and Expanded</title>
            <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Age Cohort 2: 7 to &lt;12 Years: Mini and Expanded</title>
            <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Age Cohort 3: 3 to &lt;7 Years: Mini</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
          </group>
          <group group_id="O4">
            <title>Age Cohort 3: 3 to &lt;7 Years: Expanded</title>
            <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of GZR at Steady State</title>
          <description>The CL/F of GZR at steady state (Week 4) was determined in each cohort.</description>
          <population>No participants are included in the analysis as the CL/F of GZR was not calculable due to nonlinear PK.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 36 weeks for nonserious AEs (NSAEs) and serious AEs (SAEs), and up to approximately 49 weeks for all-cause mortality.</time_frame>
      <desc>All participants who received ≥1 dose of study drug are included. All-cause mortality is based on all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Age Cohort 1: 12 to &lt; 18 Years</title>
          <description>Pediatric participants 12 to &lt;18 years of age received EBR/GZR 50 mg/100 mg FDC tablets once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Age Cohort 2: 7 to &lt; 12 Years</title>
          <description>Participants who are 7 to &lt;12 years of age received EBR/GZR 30 mg/60 mg pediatric granules once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Age Cohort 3 Mini: 3 to &lt; 7 Years</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR (weight-based dosing) once daily for 12 weeks. The Mini cohort consists of the first 7 participants enrolled into Age Cohort 3. Participants &lt;20 kg received EBR/GZR 15 mg/30 mg, and participants ≥20 kg received EBR/GZR 15 mg/50 mg.</description>
        </group>
        <group group_id="E4">
          <title>Age Cohort 3 Expanded: 3 to &lt; 7 Years</title>
          <description>Participants who are 3 to &lt;7 years of age received a pediatric formulation of EBR/GZR 25 mg/50 mg once daily for 12 weeks. The Expanded cohort consists of 11 participants enrolled after the Mini Cohort of 7 participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Behaviour disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Provisional tic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of this study may be published or presented at scientific meetings. The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

